{"id":50628,"date":"2022-11-08T18:02:21","date_gmt":"2022-11-08T17:02:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/"},"modified":"2022-11-08T18:02:21","modified_gmt":"2022-11-08T17:02:21","slug":"poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/","title":{"rendered":"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>TWYMEEG<sup>\u00ae<\/sup> (Imeglimin) net sales in Japan for the quarter (July-September) grew four-fold over the prior quarter, in part due to the lifting of the prescription days limitation in September 2022, as recently reported by Sumitomo Pharma<\/b>\n<\/li>\n<li>\n<b>Phase 2 NASH Trial (DESTINY-1) for PXL065 met its primary efficacy endpoint for liver fat content reduction at 36 weeks for all doses; PXL065 prioritized for further development in NASH based on positive results from the DESTINY-1 trial<\/b>\n<\/li>\n<li>\n<b>PXL770 development to focus exclusively on rare diseases, driven by promising data which showed strong potential in multiple rare metabolic indications<\/b>\n<\/li>\n<li>\n<b>Extension of the cash runway through at least February 2023 with debt restructuring agreement with IPF Partners (IPF) and equity-linked financing facility with Iris Capital Investment (IRIS)<\/b>\n<\/li>\n<li>\n<b>As of September 30, 2022, cash and cash equivalents were EUR 17.1 million (USD 16.6 million)<\/b>\n<\/li>\n<\/ul>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxel.com%2F&amp;esheet=52964011&amp;newsitemid=20221108005885&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=d411c40ea46d96f02b105b5bc29be8ec\" rel=\"nofollow noopener\" shape=\"rect\">POXEL SA<\/a> (Euronext : POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/4\/Logo_Without_Background.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/21\/Logo_Without_Background.jpg\"><\/a><\/p>\n<p>\n\u201c<i>This quarter\u2019s royalty revenues from TWYMEEG, marketed in Japan by Sumitomo Pharma for Type 2 diabetes, increased four-fold over the prior quarter, in part due to the removal of prescribing restrictions after the initial year on the market. The royalty stream from TWYMEEG\u2019s growth is poised to deliver significant value to Poxel<\/i>,\u201d noted Thomas Kuhn, Chief Executive Officer of Poxel. \u201c<i>From our clinical programs, our DESTINY-1 Phase 2 Trial for PXL065 in NASH recently reported positive results, especially with respect to <\/i><i>fibrosis which represents the highest unmet need in non-cirrhotic NASH.<\/i><i> This is an important milestone for Poxel, but also more broadly for NASH, for which there is still no approved treatment.<\/i><i> <\/i><i>Based on these results, we are prioritizing PXL065 in NASH and are actively looking for a partner to advance its development. <\/i><i>By <\/i><i>leveraging the 505(b)(2) regulatory pathway, the extensive safety database of the parent molecule, and our recent Phase 2 results, we are well-positioned amongst other drugs in development for future development. In addition, PXL770 is a Phase 2 ready asset that is focused exclusively on rare diseases, starting with adrenoleukodystrophy and autosomal-dominant polycystic kidney disease<\/i>.\u201d\n<\/p>\n<p>\n<b>Clinical Updates<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPositive topline results were announced for the Phase 2 trial for the treatment of NASH (DESTINY-1) for PXL065 stating that the primary efficacy endpoint was met. PXL065-treated patients achieved statistically significant improvements in the relative decrease in liver fat content measured by magnetic resonance imaging estimated proton density fat fraction (MRI<b>&#8211;<\/b>PDFF) at 36-weeks for all doses. Histology findings from paired liver biopsies showed strong improvement in fibrosis without worsening of NASH, consistent with dose-dependent reduction of all biomarkers related to fibrinogenesis and fibrosis risk scores. Additional dose-dependent benefits on glucose control and indices of insulin sensitivity were also observed. PXL065 was observed to be safe and well tolerated with no dose-dependent increase in body weight and no increased lower extremity edema vs. placebo. The safety profile is consistent with reduced PPARg-mediated side effects vs. published results of pioglitazone.\n<\/li>\n<li>\nIn adrenoleukodystrophy (ALD), PXL770 is prepared to advance into a Phase 2a biomarker proof-of-concept (POC) clinical trial in male patients with adrenomyeloneuropathy (AMN), the most common ALD subtype. The 12-week study will evaluate pharmacokinetics, safety and potential for efficacy based on relevant disease biomarkers, such as the effect on very long chain fatty acids (VLCFA), the characteristic plasma marker of the disease. Considering the DESTINY-1 results for PXL065 in NASH, which validated the deuterium-modified thiazolidinedione (TZD) platform, a second identical study continues to be planned in order to assess the potential of the deuterium-modified TZD platform with PXL065 in ALD. ALD studies are expected to initiate as soon as possible, subject to additional financing.\n<\/li>\n<li>\nPXL770 was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD).\n<\/li>\n<\/ul>\n<p>\n<b>TWYMEEG<sup>\u00ae<\/sup> (Imeglimin)<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTWYMEEG net sales in Japan for the quarter (July-September) grew significantly to JPY 0.4 billion (EUR 2.5 million)<sup>1<\/sup>, over the prior quarter (April-June) of JPY 0.1 billion (EUR 0.6 million)1 as recently reported by Sumitomo Pharma. As of September 1st, initial launch year restrictions for TWYMEEG which limited new products to two weeks prescriptions have been lifted. Sumitomo Pharma\u2019s forecast for net sales of TWYMEEG in Japan is JPY 1.5 billion (EUR 10.6 million)1 for fiscal year 2022 (April 2022 to March 2023). Based on the current forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales in Japan through the Sumitomo Pharma fiscal year 2022. As part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of Imeglimin, independent of the level of sales. Since TWYMEEG\u2019s launch in September 2021, Sumitomo Pharma\u2019s commercial efforts have leveraged TWYMEEG\u2019s potential to be used both in combination with other treatments, such as DPP4i\u2019s, which are the most prescribed treatments for Japanese Type-2-Diabetes patients, and as monotherapy.\n<\/li>\n<\/ul>\n<p>\n<b>Financing<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn August, the Company announced that it restructured its debt with IPF, resulting in the postponement of the Q3 2022 and Q4 2022 amortization payments under the existing debt facility, and lowering certain financial covenants until the end of January 2023. As part of the restructuring, the Company agreed to certain additional commitments which include the increase of the amounts due to IPF and potential partial early repayments of the debt.\n<\/li>\n<li>\nConcurrently, the Company entered into an equity-linked financing arrangement with IRIS for an initial gross amount of EUR 4 million, with the option, at the latest on December 31, 2022, and, at the Company\u2019s sole discretion, to draw a second and third tranche of up to EUR 1 million each.\n<\/li>\n<li>\nAs a result of these two agreements, the Company expects that its resources will be sufficient to fund its operations and capital expenditure requirements through at least February 2023.\n<\/li>\n<\/ul>\n<p>\n<b>Event after the Period<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nOn November 7, Stephen Harrison, MD, President of the Summit Clinical Research, presented DESTINY-1 Phase 2 Results for PXL065 in NASH at The Liver Meeting<sup>\u00ae<\/sup> 2022, hosted by the American Association for the Study of Liver Diseases (AASLD).\n<\/li>\n<\/ul>\n<p>\n<b>Third Quarter and Nine Months Ended September 30, 2022 Cash and Revenue<\/b>\n<\/p>\n<p>\n<b>Cash<\/b>\n<\/p>\n<p>\nAs of September 30, 2022, total cash and cash equivalents were EUR 17.1 million (USD 16.6 million), as compared to EUR 16.1 million at June 30, 2022.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwrightsingle bwsinglebottom bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>EUR (in thousands)<\/i>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwrightsingle bwrowaltcolor0 bwpadl0 bwsinglebottom bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q3 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwrowaltcolor0 bwpadl0 bwsinglebottom bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q2 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrightsingle bwrowaltcolor0 bwpadl0 bwsinglebottom bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q1 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwrowaltcolor0 bwpadl0 bwsinglebottom bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q4 2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwrightsingle bwsinglebottom bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash\n<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n15,062\n<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n16,143\n<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n24,043\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n28,753\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwrightsingle bwsinglebottom bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash equivalents\n<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n2,000\n<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwsinglebottom bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n3,534\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwrightsingle bwsinglebottom bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwrightsingle bwpadl0 bwsinglebottom bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total cash and cash equivalents*<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>17,062<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>16,143<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>24,043<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>32,287<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwpadl2\" colspan=\"5\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>Unaudited data<\/i>\n<\/p>\n<p class=\"bwcellpmargin\">\n<i>\u00a0<\/i>\n<\/p>\n<p class=\"bwcellpmargin\">\n<i>* Net financial debt (excluding IFRS 16 impacts and derivative debts) was EUR 16.8 million at the end of Q3 2022 as compared to EUR 17.3 million at the end of Q2 2022.<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nBased on:\n<\/p>\n<ol class=\"bwlistlowroman\">\n<li>\nits cash position at September 30, 2022,\n<\/li>\n<li>\nthe current development plan of the Company, excluding the initiation of Phase 2a clinical proof-of-concept (POC) biomarker studies for PXL065 and PXL770 in adrenomyeloneuropathy (AMN),\n<\/li>\n<li>\nthe cash forecast approved by the Board of Directors of the Company, that does not include, as a conservative approach, any net royalties from Imeglimin in Japan,\n<\/li>\n<li>\na strict control of its operating expenses, and\n<\/li>\n<li>\nthe amendment to the IPF debt facility with the postponement of the Q3 2022 and Q4 2022 amortization payments until end of February 2023, as well as a full drawdown of all tranches of the equity-linked financing arrangement with IRIS for a total amount of EUR 6 million, before December 31, 2022,\n<\/li>\n<\/ol>\n<p>\nthe Company expects that its resources will be sufficient to fund its operations and capital expenditure requirements through at least February 2023.\n<\/p>\n<p>\nThe Company is actively pursuing additional financing options, including ongoing active partnership discussions related to its programs.\n<\/p>\n<p>\n<b>Nine Months 2022 Revenue<\/b>\n<\/p>\n<p>\nPoxel reported revenues of EUR 286 thousand for the nine months ended September 30, 2022, as compared to EUR 13.3 million during the corresponding period in 2021, which mostly reflected the EUR 13.2 million milestone payment for the approval of TWYMEEG in Japan on June 23, 2021.\n<\/p>\n<p>\nRevenue for the first nine months of 2022 mostly reflects the JPY 40 million (EUR 286 thousand) of royalty revenue from Sumitomo Pharma which represents 8% of TWYMEEG net sales in Japan. Based on the current forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales in Japan through the Sumitomo Pharma fiscal year 2022 (April 2022 to March 2023). As part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of Imeglimin, independent of the level of sales.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEUR\n<\/p>\n<p class=\"bwcellpmargin\">\n<i>(in thousands)<\/i>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Sept. 2022<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>9 months<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q3 2022<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>H1 <\/b><b>2022<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>6 months<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Sept. 2021<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>9 months<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q3 <\/b><b>2021<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>H1 <\/b><b>2021<\/b>\n<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>6 months<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSumitomo Pharma Agreement\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n286\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n203\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n83\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n13,274\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n13,274\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total revenues<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>286<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>203<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>83<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>13,274<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>&#8211;<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>13,274<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<i>Unaudited data<\/i>\n<\/p>\n<p>\n<b>Planned Presentations and Participation at the Following Upcoming Events<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nALD Connect 2022 Annual Meeting &amp; Patient Learning Academy, November 11, 2022\n<\/li>\n<li>\nJefferies Healthcare Conference, London, UK, November 15-17, 2022\n<\/li>\n<li>\nODDO BHF Forum (virtual), January 9-10, 2023\n<\/li>\n<li>\nDegroof Petercam\u2019s Healthcare Conference, Brussels, Belgium, January 26, 2023\n<\/li>\n<\/ul>\n<p>\n<b>Next Financial Press Release: <\/b>Fourth Quarter 2022 Financial Statement expected on February 15, 2023\n<\/p>\n<p>\n<b>About Poxel SA<\/b>\n<\/p>\n<p>\nPoxel is a <b>clinical stage biopharmaceutical company<\/b> developing <b>innovative treatments for chronic serious diseases with metabolic pathophysiology<\/b>, including <b>non-alcoholic steatohepatitis (NASH)<\/b> and rare disorders. For the treatment of NASH, <b>PXL065<\/b> (deuterium-stabilized <i>R<\/i>-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of <b>PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). <b>TWYMEEG<sup>\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.\n<\/p>\n<p>\nFor more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=52964011&amp;newsitemid=20221108005885&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=2&amp;md5=ef8b773ec72660f3c553499ca6ae35b1\" rel=\"nofollow noopener\" shape=\"rect\">www.poxelpharma.com<\/a>\n<\/p>\n<p>\nAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company\u2019s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould\u201d and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company\u2019s control that could cause the Company\u2019s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.\n<\/p>\n<p>\n__________________________<br \/>\n<br \/><i><b><sup>1<\/sup><\/b><\/i> <i>Currency exchange rate at Sept 30, 2022<\/i>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor relations \/ Media<\/b>\n<\/p>\n<p>\nAur\u00e9lie Bozza<br \/>\n<br \/>Investor Relations &amp; Communication Senior Director<br \/>\n<br \/><a target=\"_blank\" href=\"mai&#108;&#116;&#111;&#x3a;&#x61;&#x75;&#x72;&#x65;&#x6c;ie&#46;&#98;&#111;&#122;&#122;&#x61;&#x40;&#x70;&#x6f;&#x78;&#x65;lph&#97;&#114;&#109;&#x61;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;&#117;r&#x65;&#108;i&#x65;&#46;b&#x6f;&#122;z&#x61;&#64;p&#x6f;&#120;e&#x6c;&#112;h&#x61;&#114;m&#x61;&#46;c&#x6f;&#109;<\/a><br \/>+33 6 99 81 08 36\n<\/p>\n<p>\nElizabeth Woo<br \/>\n<br \/>Senior Vice President, Investor Relations &amp; Communication<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#105;l&#x74;&#x6f;&#58;e&#x6c;&#x69;&#122;ab&#x65;&#116;&#104;&#46;&#x77;&#x6f;&#111;&#64;&#x70;&#x6f;&#120;&#101;l&#x70;&#x68;&#97;r&#x6d;&#x61;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">el&#105;&#122;&#x61;&#x62;&#x65;&#x74;h&#46;&#119;&#111;&#x6f;&#x40;&#x70;&#x6f;xe&#108;&#112;&#104;&#x61;&#x72;&#x6d;&#x61;&#46;c&#111;&#109;<\/a>\n<\/p>\n<p>\nNewCap<br \/>\n<br \/>Emmanuel Huynh or Arthur Rouill\u00e9<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;t&#x6f;&#58;&#x70;&#x6f;x&#x65;&#108;&#64;&#x6e;&#101;&#x77;&#99;a&#x70;&#46;e&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">p&#111;&#x78;&#x65;l&#64;&#x6e;&#x65;w&#99;&#97;&#x70;&#x2e;e&#117;<\/a><br \/>+33 1 44 71 94 94\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TWYMEEG\u00ae (Imeglimin) net sales in Japan for the quarter (July-September) grew four-fold over the prior quarter, in part due to the lifting of the prescription days limitation in September 2022, as recently reported by Sumitomo Pharma Phase 2 NASH Trial (DESTINY-1) for PXL065 met its primary efficacy endpoint for liver fat content reduction at 36 &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50628","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TWYMEEG\u00ae (Imeglimin) net sales in Japan for the quarter (July-September) grew four-fold over the prior quarter, in part due to the lifting of the prescription days limitation in September 2022, as recently reported by Sumitomo Pharma Phase 2 NASH Trial (DESTINY-1) for PXL065 met its primary efficacy endpoint for liver fat content reduction at 36 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T17:02:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/21\/Logo_Without_Background.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022\",\"datePublished\":\"2022-11-08T17:02:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/\"},\"wordCount\":1793,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005885\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/\",\"name\":\"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005885\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"datePublished\":\"2022-11-08T17:02:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005885\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221108005885\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022 - Pharma Trend","og_description":"TWYMEEG\u00ae (Imeglimin) net sales in Japan for the quarter (July-September) grew four-fold over the prior quarter, in part due to the lifting of the prescription days limitation in September 2022, as recently reported by Sumitomo Pharma Phase 2 NASH Trial (DESTINY-1) for PXL065 met its primary efficacy endpoint for liver fat content reduction at 36 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-08T17:02:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/21\/Logo_Without_Background.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022","datePublished":"2022-11-08T17:02:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/"},"wordCount":1793,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/21\/Logo_Without_Background.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/","url":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/","name":"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/21\/Logo_Without_Background.jpg","datePublished":"2022-11-08T17:02:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/21\/Logo_Without_Background.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221108005885\/en\/729413\/21\/Logo_Without_Background.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/poxel-provides-corporate-update-and-reports-cash-and-revenue-for-the-third-quarter-and-nine-months-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50628"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50628\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}